4519 — Chugai Pharmaceutical Share News
0.000.00%
Last trade - 00:00Japan's Chugai applies for approval of antibody treatment for COVID-19
Japanese shares retreat from 3-week high; drugmakers limit losses
Reached Agreement With Japanese Government Regarding Investigational Antibody Cocktail (Casirivimab And Imdevimab) For Covid-19
Table: Chugai Pharm -Q1 group results (IFRS)
Brief: Atea Pharmaceuticals Announces Chugai In-License Of AT-527 From Roche For The Treatment Of COVID-19 In Japan
Japan's Nikkei inches up on Fast Retailing gain, but market outlook caution sets in
Table: Chugai Pharm -2020 group results (IFRS)
Refinitiv Newscasts - Asia Insight: Nikkei hits 30-year high as drug makers rally on COVID-19 news
Table: Chugai Pharm -9-MTH group results (IFRS)
Japan stocks end lower as firmer yen, U.S. political uncertainty weigh
Japanese shares fall on rising yen, U.S. political uncertainty
Brief: Chugai Pharmaceutical Co Ltd Files NDA For Risdiplam For Spinal Muscular Atrophy In Japan
Table: Chugai Pharm -6-MTH group results (IFRS)
Brief: Protara Therapeutics Says Chugai Entered Into Amendment To Co's Unit's Agreement Dated June 17, 2019
Table: Chugai Pharm -Q1 group results (IFRS)
Table: Chugai Pharm -2019 group results (IFRS)
Brief: Japan's Chugai Pharma says to do a 3-for-1 stock split from June 30
Verastem Oncology: Rises on licensing agreement with Chugai Pharma
Table: Chugai Pharm -9-MTH group results (IFRS)